Single B cell technologies for monoclonal antibody discovery
OPEN ACCESS
Loading...
Author / Producer
Date
2021-12
Publication Type
Review Article
ETH Bibliography
yes
Citations
Altmetric
OPEN ACCESS
Data
Abstract
Monoclonal antibodies (mAbs) are among the most important type of biologic drugs on the pharmaceutical market, as well as for diagnostic purposes. Presently, more than 100 mAbs have been approved by the US FDA against a variety of diseases such as cancer, infectious diseases, autoimmune diseases, and neurological disorders.
Primary antigen-specific B cells are the main source for obtaining antigen-specific mAb sequences, particularly using human specimens such as peripheral blood mononuclear cells. Also, the humanization of mAbs derived from other species (e.g. mice, rats, and rabbits) has become easier and more efficient.
Currently, single B cell screening systems bear multiple advantages over other systems, such as display technologies. Particularly, the in vivo development of mAbs favors the safety profile and the overall developability. It also has reduced off-target binding to the human proteome.
Single B cell technologies have significantly evolved, becoming faster and higher throughput than before. Nonetheless, hybridoma technology, the first technique in this field, still represents an important methodology and is well known within the scientific community.
At present no gold standard exists in the field, relying on a broad variety of different single B cell systems for mAb discovery – each with its advantages and disadvantages.
Permanent link
Publication status
published
External links
Editor
Book title
Journal / series
Volume
42 (12)
Pages / Article No.
1143 - 1158
Publisher
Elsevier
Event
Edition / version
Methods
Software
Geographic location
Date collected
Date created
Subject
Organisational unit
03625 - Oxenius, Annette / Oxenius, Annette
Notes
Funding
166078 - Antibody evolution during chronic viral infections: a functional and systems immunological approach (SNF)